Mechanisms of lipotoxicity in NAFLD and clinical implications

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 2, 2011, Pages 131-140

  Ibrahim, Samar H ^a   Kohli, Rohit ^b   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Bcl 2 homology 3 only protein; c Jun N terminal kinase; C EBP homologous protein (CHOP); endoplasmic reticulum stress; free fatty acids; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Indexed keywords

DEATH RECEPTOR; FATTY ACID; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL;

APOPTOSIS; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; ESTERIFICATION; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOTOXICITY; LIVER CELL; LIVER FIBROSIS; LIVER TOXICITY; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR GENE; REVIEW;

ADIPOSE TISSUE; ADOLESCENT; ADULT; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CHILD; DIETARY FATS; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; OBESITY; TRANSCRIPTION FACTOR CHOP;

EID: 79961206915     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31822578db     Document Type: Review

References (132)

1. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782)
2. Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006;4:226-32. (Pubitemid 43199694)
3. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80. (Pubitemid 20075105)
4. Propst A, Judmaier G, Vogel W, et al. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995;108:1607.
5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048)
6. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-73. (Pubitemid 46489550)
7. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4. (Pubitemid 37430103)
8. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53. (Pubitemid 30349945)
9. Carter-Kent C, Brunt EM, Yerian LM, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;52:190-7.
10. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;50:1113-20.
11. Kohli R, Boyd T, Lake K, et al. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr 2010;50:453-6.
12. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44.
13. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002;17 (suppl):S186-90. (Pubitemid 34539308)
14. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92. (Pubitemid 32246672)
15. Nehra V, Angulo P, Buchman AL, et al. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001;46:2347-52. (Pubitemid 33042332)
16. Kusminski CM, Shetty S, Orci L, et al. Diabetes and apoptosis: lipotoxicity. Apoptosis 2009;14:1484-95.
17. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-65. (Pubitemid 37476041)
18. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-43. (Pubitemid 36929425)
19. Feldstein AE, Wieckowska A, Feldstein AE, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50: 1072-8.
20. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51. (Pubitemid 40629054)
21. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52. (Pubitemid 39071617)
22. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-38. (Pubitemid 351364588)
23. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010;30:391-401.
24. Malhi H, Bronk SF, Werneburg H, et al. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006;281: 12093-12101. (Pubitemid 43855473)
25. Wei Y, Wang D, Topczewski F, et al. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006;291:E275-81. (Pubitemid 44035286)
26. Wei Y, Wang D, Gentile CL, et al. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol Cell Biochem 2009;331:31-40.
27. Akazawa Y, Cazanave S, Mott JL, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol 2010;52:586-93.
28. Cao H, Gerhold K, Mayers JR, et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008; 134:933-44.
29. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003;100:3077-82. (Pubitemid 36356542)
30. Li ZZ, Berk M, McIntyre TM, et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009;284:5637-44.
31. Trauner M, Arrese M,Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010;1801:299-310.
32. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-90. (Pubitemid 350144772)
33. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010;139:149-53.
34. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-74. (Pubitemid 46918320)
35. Monetti M, Levin MC,Watt MJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007;6:69-78. (Pubitemid 46995777)
36. Koliwad SK, Streeper RS, Monetti M, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J Clin Invest 2010; 120:756-67.
37. Pohl J, Ring A, Hermann T, et al. Role of FATP in parenchymal cell fatty acid uptake. Biochim Biophys Acta 2004;1686:1-6. (Pubitemid 39446872)
38. Zhou J, Febbraio M,Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008;134:556-67.
39. Doege H, Baillie RA, Ortegon H, et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 2006;130:1245-58.
40. Falcon A, Doege H, Fluitt A, et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metabol 2010;299:E384-93.
41. Newberry EP, Xie Y, Kennedy S, et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J BiolChem2003;278:51664-72. (Pubitemid 38020412)
42. Greco D, Kotronen A,Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008;294:G1281-7.
43. Charlton M, Viker K, Krishnan A, et al. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 2009;49:1375-84.
44. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5.
45. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148Mvariant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
46. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
47. Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52:1281-90.
48. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362:1082-9.
49. Sabio G, Das M, Mora A, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008;322:1539-43.
50. Alkhouri N, Gornicka A, Berk MP, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2010;285:3428-38.
51. Wueest S, Rapold RA, Schumann DM, et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 2010;120:191-202.
52. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-17. (Pubitemid 39237497)
53. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
54. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360-9.
55. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29. (Pubitemid 46985379)
56. Ji C, Kaplowitz N. ER stress: can the liver cope? J Hepatol 2006; 45:321-33.
57. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011;13:184-90.
58. Kaplowitz N, Than TA, Shinohara M, et al. Endoplasmic reticulum stress and liver injury. Semin Liver Dis 2007;27:367-77. (Pubitemid 350071837)
59. Rahman SM, Schroeder-Gloeckler JM, Janssen RC, et al. CCAAT/ enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in dietinduced nonalcoholic steatohepatitis. Hepatology 2007;45:1108-17. (Pubitemid 46775772)
60. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 2004;14:20-8. (Pubitemid 38076857)
61. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002;110:1389-98. (Pubitemid 35396907)
62. Wu J, Rutkowski DT, Dubois M, et al. ATF6 alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev Cell 2007;13:351-64. (Pubitemid 47308675)
63. Yamamoto K, Sato T, Matsui T, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell 2007;13:365-76. (Pubitemid 47308680)
64. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61. (Pubitemid 39372439)
65. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006;147:943-51. (Pubitemid 43113013)
66. Puri P, Mirshahi P, Cheung P, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008;134:568-76. (Pubitemid 351173040)
67. Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009;58:693-700.
68. Flowers MT, Keller MP, Choi Y, et al. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genom 2008;33:361-72. (Pubitemid 352755738)
69. Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009;284:26591-602.
70. Barreyro FJ, Kobayashi S, Bronk SF, et al. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 2007;282:27141-54. (Pubitemid 47501972)
71. Puthalakath H, O'Reilly LA, Gunn P, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007;129:1337-49. (Pubitemid 46962086)
72. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9. (Pubitemid 39006738)
73. Wang XZ, Lawson Beth, Brewer JW, et al. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/ GADD153). Mol Cell Biol 1996;16:4273-80. (Pubitemid 26251229)
74. Yamaguchi H,Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 2004;279:45495-502. (Pubitemid 39491535)
75. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009;23:1625-37.
76. Malhi H, Barreyro FJ, Isomoto H, et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007;56:1124-31. (Pubitemid 47123245)
77. Farrell GC, Larter CZ, Hou JY, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009;24:443-52.
78. Soon RK Jr, Yan JS, Grenert JP, et al. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. Gastroenterology 2010;139:1730-9.
79. Pfaffenbach KT, Gentile CL, Nivala AM, et al. Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitatemediated cell death. Am J Physiol Endocrinol Metab 2010;298: E1027-E1035.
80. Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 2007;1773:1341-8. (Pubitemid 47125977)
81. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6. (Pubitemid 35398190)
82. Schattenberg JM, Singh R,Wang Y, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006;43:163-72. (Pubitemid 43733603)
83. Singh R, Wang Y, Xiang Y, et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009;49:87-96.
84. Yang R, Wilcox DM, Haasch DL, et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem 2007; 282:22765-74. (Pubitemid 47267371)
85. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 2006;281:21256-65.
86. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008;27:6245-51.
87. Christen V, Treves S, Duong FH, et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007;46:558-65. (Pubitemid 47344792)
88. Wang Y, Ausman LM, Russell RM, et al. Increased apoptosis in highfat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr 2008;138:1866-71.
89. Masuoka HC, Mott J, Bronk SF, et al. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009;284:30039-48.
90. Feldstein AE, Werneburg NW, Li Z, et al. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006;290:G1339-46. (Pubitemid 43788317)
91. Jabbour AM, Heraud JE, Daunt CP, et al. Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ 2009;16:555-63.
92. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004;23:2881-90. (Pubitemid 38638850)
93. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-94. (Pubitemid 38868937)
94. Mari M, Fernandez-Checa JC. Sphingolipid signalling and liver diseases. Liver Int 2007;27:440-50. (Pubitemid 46534565)
95. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006;45:42-72. (Pubitemid 43170804)
96. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-79.
97. Morales A, Lee H, Goni FM, et al. Sphingolipids and cell death. Apoptosis 2007;12:923-39. (Pubitemid 46653290)
98. Paris F, Grassmé H, Cremesti A, et al. Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes. J Biol Chem 2001;276:8297-305.
99. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev 2006;86:1237-61. (Pubitemid 44521652)
100. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006;4:185-98. (Pubitemid 44307975)
101. Feng B, Pin MY, Li Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003;5:781-92. (Pubitemid 37087166)
102. Caballero F, Fernández A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 2009;50:789-96.
103. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48:474-86.
104. Wouters K, van Bilsen K, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 2010;584:1001-5.
105. Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
106. Sanyal AJ, Chalasani N, KowdleyKV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-85.
107. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68.
108. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003; 124:248-50. (Pubitemid 36055357)
109. Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 335:855-9. (Pubitemid 26304067)
110. Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995;85:43-9.
111. Xie Q, Khaoustov VI, Chung CC, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002;36:592-601. (Pubitemid 34977169)
112. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137-40. (Pubitemid 44300242)
113. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010;59:1899-905.
114. Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004;37:1499-507. (Pubitemid 39349251)
115. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008;42:413-8. (Pubitemid 351450629)
116. Ibrahim SH, Akazawa Y, Cazanave SC, et al. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol 2011;54:765-72.
117. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009;50:1421-30.
118. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 2010;5:71-85.
119. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002;282:G193-9.
120. Serviddio G, Sastre J, Bellanti F, et al. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008;29:22-35. (Pubitemid 351312221)
121. Li Z, Berk M, McIntyre TM, et al. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008; 47:1495-503. (Pubitemid 351702733)
122. Maurer U, Charvet C, Wagman AS, et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60. (Pubitemid 43376126)
123. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004;24:9993-10002. (Pubitemid 39463581)
124. Shinohara M, Ybanez MD, Win S, et al. Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem 2010;285:8244-55.
125. Pagliassotti MJ, Wei Y, Wang D. Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology 2007;148:3338-45. (Pubitemid 46996986)
126. Vallerie SN, Hotamisligil GS. The role of JNK proteins in metabolism. Sci Transl Med 2010;2:60rv5.
127. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-502. (Pubitemid 39193189)
128. Kohli R, Pan X, Malladi P, et al. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 2007;282: 21327-21336. (Pubitemid 47099964)
129. Yu J, Chu ES, Wang R, et al. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology 2010;138:694-704.
130. Wang RQ, Nan YM, Wu WJ, et al. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis 2011;10:31.
131. Nan Y, Wang R, Zhao S, et al. Heme oxygenase-1 prevents nonalcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. Lipids Health Dis 2010;9:124.
132. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. (Pubitemid 351975537)